# A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

> **NCT07153796** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Blinatumomab
- **DRUG:** Mini-CVD
- **DRUG:** MTX/ARA-C

## Key facts

- **NCT ID:** NCT07153796
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-30
- **Primary completion:** 2031-09-30
- **Final completion:** 2033-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07153796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07153796, "A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07153796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*